Biotech Predicts Reduced COVID Sales and Signals Potential M&As

May 9, 2022

Despite tripling their sales last quarter, BioNTech’s CFO Jens Holstein signaled to investors that mergers and collaborations may be in the company’s future in a Q1 call on Monday, May 9th. The expected reduction in sales is a result of the pandemic seemingly transitioning to an endemic state, which BioNTech’s rival Moderna says reflects, “a seasonal sales pattern.”

According to Nicole DeFeudis,” BioNTech is working on several follow-on and next-gen programs that could target specific variants like Omicron. And while the FDA has OK’d a fourth booster dose for older adults and those who are immunocompromised, BioNTech is still testing the efficacy of a fourth dose in all adults over 16. The company is planning to roll out safety and immunogenicity data for its Omicron-adapted and bivalent vaccine programs in the coming weeks, execs said on the call.”

To read more, click here.

(Source: Endpoints News, May 9th, 2022)

Share This Story!